Abilify Tablet
NDC Package 59148-009-95
Package Information
Abilify (aripiprazole) tablets is aripiprazole is used to treat certain mental/mood disorders (such as bipolar disorder, schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder). This formulation utilizes a tablet delivery system. Marketed by Otsuka America Pharmaceutical, Inc., this product is identified by NDC 59148-009 and is authorized under FDA application NDA021436.
Identification & Billing
- RxCUI: 349490 - ARIPiprazole 15 MG Oral Tablet
- RxCUI: 349490 - aripiprazole 15 MG Oral Tablet
- RxCUI: 349545 - ARIPiprazole 10 MG Oral Tablet
- RxCUI: 349545 - aripiprazole 10 MG Oral Tablet
- RxCUI: 349547 - ARIPiprazole 30 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59148 - Otsuka America Pharmaceutical, Inc.
- 59148-009 - Abilify
- 59148-009-95 - 7 TABLET in 1 BLISTER PACK
- 59148-009 - Abilify
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (59148-009). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59148-009-95 identifies a specific commercial package of 7 tablet in 1 blister pack of Abilify, a human prescription drug labeled by Otsuka America Pharmaceutical, Inc.. This tablet is formulated for oral use and contains aripiprazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Otsuka America Pharmaceutical, Inc. on November 15, 2002. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Aripiprazole is used to treat certain mental/mood disorders (such as bipolar disorder, schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder). It may also be used in combination with other medication to treat depression. Aripiprazole is known as an antipsychotic drug (atypical type). It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters). This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. Aripiprazole can treat severe mood swings and decrease how often mood swings occur.
How is this Otsuka America Pharmaceutical, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59148000995. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.